Kewaunee Scientific Revenue declined to $66.32 million in the three months ended July 31, 2026, while Earnings attributable to shareholders fell to $1.706 million, or $0.58 per diluted share. Investors face lower sales and backlog, although gross Margin improved to 29.6% and Operating Activities generated $1.976 million.
Key Highlights
- Gross profit margin increased to 29.6%, supported by improved performance in the International segment.
- Order Backlog was $169.0 million at July 31, 2026, down from $205.0 million a year earlier.
- Net earnings attributable to Kewaunee Scientific shareholders fell to $1.706 million from $3.093 million.
Kewaunee Scientific Corporation (NASDAQ: KEQU) generated $66.32 million of revenue in the three months ended July 31, 2026, down from $71.104 million in the comparable period. Net earnings attributable to Kewaunee Scientific shareholders fell to $1.706 million from $3.093 million, while Diluted Earnings per Share declined to $0.58 from $1.04. Net earnings for the quarter were $1.843 million. The quarter paired weaker sales with lower operating profit, although interest expense also declined. Kewaunee Scientific reported $3.158 million of operating profit, $2.560 million of profit before income taxes and $717,000 of income tax expense.
Revenue And Earnings Decline
Cost of products sold was $46.681 million, compared with $50.174 million in the prior-year period. Gross profit reached $19.639 million versus $20.930 million, while operating expenses increased to $16.481 million from $16.120 million. Other income, net, was $28,000, down from $168,000. Interest expense decreased to $626,000 from $1.058 million, reflecting changes in bank and other borrowings and interest rates. The effective income tax rate was 28.0%, compared with 19.4% in the comparable period. Basic Earnings Per Share were $0.59, down from $1.08. The weighted-average basic share count was 2,880,000, compared with 2,851,000, while diluted weighted-average shares were 2,921,000 versus 2,963,000.
Domestic Demand Weighs On Sales
LPG revenue was $50.868 million, down from $54.352 million, a 6.4% decrease. International revenue was $15.452 million, compared with $16.752 million, a 7.8% decline. Revenue recognized over time totaled $46.559 million, including $31.107 million from LPG and $15.452 million from International. Point-in-time revenue was $19.761 million, all from LPG. The Gross Profit Margin increased to 29.6% of sales from 29.4%. The improvement primarily came from stronger margin performance in the International segment.
Backlog And Cash Movement
The company said demand is difficult to predict because it operates as a subcontractor or supplier to dealers for subcontractors. Operating activities generated $1.976 million of cash during the quarter. The result was primarily driven by operations, a $0.5 million decrease in receivables, a $0.7 million decrease in inventories and a $1.0 million increase in deferred revenue. Those inflows were partly offset by a $3.0 million decrease in Accounts Payable and other accrued expenses and a $1.2 million change in other items, net. Investing activities used $772,000 related to capital expenditures, while financing activities used $2.499 million. Working Capital was $56.716 million at July 31, 2026, compared with $57.046 million at April 30, 2026. The current-assets-to-current-liabilities ratio was 2.2-to-1.0 at both dates.
Kewaunee Scientific said future demand depends on planned laboratory construction projects and the progress of projects already under construction. Its ability to predict demand remains limited.




Please wait processing your request...